刚刚！北大医药公告重大利空！

Core Viewpoint - The company faces significant risks due to its heavy reliance on a major client, Beijing University International Hospital, with the termination of their business cooperation expected to lead to substantial revenue and profit declines starting in mid-2025 [2][4][5]. Business Dependency - Beijing Beiyi Pharmaceutical Co., Ltd. has been the sole provider of procurement, logistics, and distribution services for medical equipment, surgical instruments, and consumables to the International Hospital, with a contract set to expire in May 2025 [3][4]. - The company has not identified alternative business opportunities, which raises concerns about a complete halt in operations and potential layoffs [4][5]. Financial Impact - The anticipated financial impact includes a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit reduction of about 40 million yuan (28.99% of the latest audited net profit) from June 2025 to the end of that year [2][4]. - From 2026 onwards, the company may face a revenue drop of around 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decline of approximately 68.69 million yuan (49.78% of the latest audited net profit) [2][4]. Transition Efforts - The company is actively exploring new directions for the transformation of Beiyi Pharmaceutical to mitigate the impact of the business termination, although the success of this transition remains uncertain [5]. - If the company fails to find a viable transformation path, it may face further operational challenges and potential shutdown [5]. Historical Context - The company has undergone several name changes and has a history of significant financial fluctuations, with net profits reported at 55.61 million yuan in 2022, 44.36 million yuan in 2023, and 137.99 million yuan in 2024 [6][8]. - As of March 31, 2025, the company reported a total revenue of approximately 502.36 million yuan, with a slight growth rate of 1.70% [8].